Biotech After a single patient drives a big stock surge, Patrick Soon-Shiong makes his case to investors By Rebecca Robbins @rebeccadrobbins
January 14, 2020
Dr. Patrick Soon-Shiong in 2016. Darren McCollester/Getty Images
S AN FRANCISCO — Not many investors had pegged the long-stagnant immunotherapy developer NantKwest as one of the big stock winners of this week.
But on Monday, the first day of the J.P. Morgan Healthcare Conference, the stock soared 91% after the company’s founder and CEO, Dr. Patrick Soon-Shiong , gave an unusual television interview. With characteristic showmanship, the biotech billionaire announced that one patient with pancreatic cancer saw a complete disease response after receiving five infusions of a treatment his companies are developing.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTED Log In | Learn More What is it? STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day Online intelligence briefings Frequent opportunities to engage with veteran beat reporters and industry experts Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. GET STARTED
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology